Full-Time

Chief Accounting Officer

Deadline 8/14/26
Fortrea

Fortrea

10,001+ employees

Global CRO providing Phase I-IV trials

No salary listed

Durham, NC, USA

Hybrid

Occasional domestic and international travel of approximately 10–20% may be required.

Bachelor's

Category
Accounting (1)
Required Skills
ERP
Mergers & Acquisitions (M&A)

Get referred to Fortrea

See people who can refer or advise you

Requirements
  • A bachelor's degree in Accounting, Finance, Business Administration, or a related discipline.
  • A Certified Public Accountant (CPA) or equivalent professional accounting qualification is required where applicable to the role and jurisdiction.
  • Comprehensive knowledge of United States generally accepted accounting principles, Securities and Exchange Commission reporting, Sarbanes-Oxley compliance, internal controls, financial statement preparation, external audit processes, public-company reporting obligations, and complex technical accounting matters.
  • Deep experience with revenue recognition in project-based, long-term contract environments, including Accounting Standards Codification 606, legacy Accounting Standards Codification 605 considerations, contract modifications, pass-through costs, reimbursables, and contract research organization-specific revenue accounting practices.
  • Experience overseeing global statutory reporting, local audits, legal entity accounting, and coordination across regional finance teams.
  • Experience supporting Securities and Exchange Commission filings, including Form 10-K, Form 10-Q, earnings materials, disclosure controls, and Audit Committee reporting.
  • Experience leading accounting activities related to mergers and acquisitions, divestitures, integrations, purchase accounting, and complex restructuring initiatives.
  • Ability to lead global accounting teams and external contractors, manage complex reporting deadlines, advise executive stakeholders, and operate effectively in a matrixed, global environment across Finance, Legal, Tax, Treasury, Investor Relations, Human Resources, Information Technology, and business leadership.
  • Strong business judgment, executive communication, enterprise leadership, problem-solving, collaboration, change leadership, and ethical decision-making skills.
  • Relevant and equivalent experience and successful project outcomes may be considered in lieu of educational requirements.
  • 15+ years of progressive accounting, controllership, external reporting, audit, or finance leadership experience, including substantial experience in a public-company environment.
  • 10+ years of experience in senior leadership, such as Chief Accounting Officer, Corporate Controller, Vice President of Finance and Accounting, or an equivalent senior finance leadership role.
  • Executive-level experience leading accounting organizations, external financial reporting, Sarbanes-Oxley and control frameworks, global close processes, and audit relationships.
  • Experience presenting to or supporting Audit Committee, Board, executive leadership, external auditor, and investor-facing processes.
  • Experience leading finance transformation, process automation, shared services, enterprise resource planning or finance systems initiatives, and global operating model improvements.
  • Ability to work in an upright and/or stationary position for 6–8 hours per day.
  • Repetitive hand movement of both hands with the ability to make fast, simple, repeated movements of the fingers, hands, and wrists to operate lab equipment.
  • Occasional crouching and stooping, with frequent bending and twisting of the upper body and neck.
  • Ability to access and use a variety of computer software developed both in-house and off-the-shelf.
  • Light to moderate lifting and carrying, or moving objects, including luggage and a laptop computer, with a maximum lift of 15–20 pounds.
  • Regular and consistent attendance.
  • Varied hours may be required.
  • Work is performed in an office environment with exposure to electrical office equipment.
  • Occasional drives to site locations may be required.
Responsibilities
  • Lead Fortrea’s global accounting function, including corporate accounting, record-to-report, consolidation, close management, payroll-related accounting, technical accounting, and accounting operations.
  • Oversee timely and accurate monthly, quarterly, and annual close processes, driving a disciplined close calendar, clear ownership, and resolution of material accounting matters.
  • Lead external financial reporting processes, including Securities and Exchange Commission reporting, financial statement preparation, earnings support, and related disclosure controls in partnership with the Chief Financial Officer, Legal, Investor Relations, and external advisors.
  • Establish, maintain, and interpret accounting policies, ensuring compliance with United States generally accepted accounting principles, Securities and Exchange Commission requirements, applicable company policies, and evolving regulatory standards.
  • Provide technical accounting leadership for complex transactions, including revenue recognition, business combinations, restructuring, impairments, equity, compensation, leases, debt, and other significant accounting matters.
  • Own the design, execution, and continuous improvement of internal control over financial reporting, including Sarbanes-Oxley compliance, control remediation, and partnership with Internal Audit and external auditors.
  • Lead the external auditor relationship and annual audit process, ensuring audit readiness, quality deliverables, issue resolution, and transparent escalation of key matters.
  • Support Audit Committee and executive leadership discussions by preparing clear, concise updates on financial reporting, technical accounting, finance policies, control status, audit progress, and critical projects.
  • Promote and establish a culture of accountability, ethical conduct, compliance, and strong financial governance across the global accounting organization.
  • Identify, assess, and escalate financial reporting, control, compliance, and audit risks with clear recommendations and executive-level judgment.
  • Drive accounting transformation initiatives, including process standardization, automation, shared services optimization, finance systems improvements, scalable operating model design, and stronger end-to-end accounting workflows.
  • Co-manage external contractor partnerships.
  • Identify and sponsor opportunities to improve close efficiency, data quality, reporting reliability, transparency, controls, and controllership capabilities while reducing manual effort across regions and functions.
  • Support potential mergers and acquisitions, integration, capital structure, and other strategic processes.
  • Build, lead, and develop a high-performing global accounting team with clear roles, succession depth, technical capability, and strong engagement.
  • Provide enterprise-level counsel to the Chief Financial Officer and senior leaders on accounting implications, reporting risks, operational decisions, and regulatory considerations.
  • Collaborate with FP&A, Tax, Treasury, Investor Relations, Legal, Human Resources, Procurement, and business unit leaders while representing Accounting in cross-functional governance forums, transformation programs, and strategic initiatives requiring financial reporting or control expertise.
  • Perform all other duties as needed or assigned.
  • Travel occasionally domestically and internationally, estimated at approximately 10–20%, based on business, audit, leadership, and transformation needs.
Desired Qualifications
  • Experience in global and regulated industries; clinical research, pharmaceutical services, healthcare, technology, or similarly complex environments are advantageous.

Fortrea is a global contract research organization that provides clinical development services for the life sciences industry. It offers full service, functional service, and hybrid outsourcing models across Phase I–IV trials, clinical pharmacology, and consulting, serving biotech, biopharma, medical devices, and diagnostics. Its work is delivered through a network of investigators and specialized teams in approximately 100 countries, supporting trial design, execution, data management, and regulatory compliance. Fortrea’s approach combines its legacy experience from Covance and Labcorp with a pureplay CRO model to deliver fit-for-purpose solutions and agile project delivery. This positions it to manage trials across more than 20 therapeutic areas with scientific rigor and operational excellence. The company aims to bring predictability to clinical trial execution and help clients turn research ideas into real-world outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

2023

Get referred to Fortrea

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fortrea raised 2026 revenue guidance to $2.62 billion-$2.69 billion on July 29, 2026.
  • Book-to-bill stayed above 1.0x for four straight quarters, supporting backlog conversion.
  • Q2 2026 operating margin improved to 2.2%, showing cost cuts and discipline are working.

What critics are saying

  • Jason Knoblauch is on paid leave after Delaware Chancery restraints; finance leadership remains unstable.
  • Q2 2026 revenue still fell 4.5%, signaling weak demand and pricing pressure.
  • Large-pharma FSP renewals already forced pricing concessions; another renewal cycle can crush 2027 margins.

What makes Fortrea unique

  • Fortrea’s April 7, 2026 FIT platform embeds AI into clinical trial operations.
  • Fortrea spans phase I-IV trials across roughly 100 countries with deep investigator-site reach.
  • Fortrea’s 2023 Labcorp spinout preserved a focused CRO model for pharma, biotech, and devices.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

27%

1 year growth

27%

2 year growth

27%
Yahoo Finance
Aug 15th, 2026
Fortrea shares fall 5.7% despite Q2 revenue beat of $678M in drug development sector review

Fortrea, a contract research organisation spun off from Labcorp in 2023, reported Q2 revenues of $678.2 million, down 4.5% year-on-year but exceeding analyst expectations by 4.7%. The company helps pharmaceutical, biotech, and medical device companies develop products through clinical trials and support services. Chief executive officer Anshul Thakral said the results reflected continued progress against the company's strategy and disciplined execution. The quarter saw Fortrea beat earnings per share estimates, with full-year revenue guidance surpassing analyst expectations. Among the eight drug development inputs and services stocks tracked, revenues collectively beat consensus estimates by 4.1%. Despite posting the slowest revenue growth in the group, the sector's share prices rose 12.6% on average. Fortrea's stock fell 5.7% following the results and currently trades at $19.52.

Yahoo Finance
Jul 29th, 2026
Fortrea beats Q2 revenue estimates despite 4.5% decline, raises full-year guidance to $2.66B

Fortrea Holdings reported second-quarter revenue of $678.2 million, exceeding analyst estimates by 4.7% despite a 4.5% year-on-year decline. The clinical research company's adjusted earnings per share of $0.23 beat consensus estimates by 27.2%. The company raised its full-year revenue guidance to $2.66 billion at the midpoint, up 2.1% from previous guidance and 1.8% above analyst expectations. Full-year EBITDA guidance of $212.5 million also surpassed estimates. Operating margin improved significantly to 2.2%, compared to negative 46.5% in the same quarter last year. CEO Anshul Thakral said the results reflect continued progress against the company's strategy. However, analysts project revenue to remain flat over the next 12 months, suggesting limited near-term growth prospects.

Yahoo Finance
Jun 26th, 2026
Fortrea appoints Jason Knoblauch as CFO, reiterates $2.55B-$2.65B revenue guidance

Fortrea, a global contract research organisation, has appointed Jason Knoblauch as chief financial officer, effective 6 July 2026. He will succeed Jill McConnell, who is stepping down after helping establish Fortrea as an independent CRO. Knoblauch joins from Clario, where he served as CFO. He previously held the CFO position at Curia and various financial leadership roles at Pharmaceutical Product Development, including interim CFO and helping lead the company to a successful IPO in 2020. Earlier, he worked in PricewaterhouseCoopers' Transaction Services practice. The company reiterated its 2026 financial guidance, targeting revenues between $2,550 million and $2,650 million, with adjusted EBITDA of $190 million to $220 million.

Stock Story, Inc
Jun 24th, 2026
Why Fortrea (FTRE) stock is trading up today.

Why Fortrea (FTRE) stock is trading up today. Anthony lee /. June 24, 2026 What happened? Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 4.6% in the morning session after Barclays raised its price target on the company's shares to $18 from $16, while maintaining an Equal Weight rating. The adjustment by analyst Luke Sergott was part of a second-quarter preview for the life science and diagnostic tools space. According to the analyst's research note, tools are "gaining favor among healthcare subsectors," a trend that is likely to continue into the earnings reporting season. Barclays expects companies in the sector to report quarterly results that are in-line with or slightly better than expectations. What is the market telling us. Fortrea's shares are extremely volatile and have had 64 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 8 months ago when the stock gained 25.3% on the news that the company reported third-quarter financial results that showed stronger-than-expected revenue and an improved outlook for the full year. For the third quarter, Fortrea announced revenues of $701.3 million, which surpassed analyst estimates. However, its adjusted earnings of $0.12 per share fell short of projections. Despite the mixed bottom-line results, investors appeared to focus on the company's future prospects. Fortrea raised its revenue guidance for the full year to a midpoint of $2.73 billion, up from its previous forecast of $2.65 billion. This improved outlook, along with the strong quarterly sales, signaled confidence in the company's growth, outweighing the earnings miss. Fortrea is up 2.9% since the beginning of the year, and at $17.30 per share, it is trading close to its 52-week high of $18.40 from January 2026. Investors who bought $1,000 worth of Fortrea's shares at the IPO in June 2023 would now be looking at an investment worth $574.58. WHILE YOU'RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You've probably never heard of it. This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.

Yahoo Finance
May 15th, 2026
Fortrea beats Q1 estimates with $636.5M revenue as biotech rebound lifts margins

Fortrea exceeded Wall Street expectations in its first quarter results, posting revenue of $636.5 million versus estimates of $627.5 million and adjusted earnings per share of $0.16 against estimates of $0.05. The clinical research services company's adjusted EBITDA reached $47 million, beating analyst estimates of $34.61 million. CEO Anshul Thakral attributed the performance to improved commercial execution and a rebound in biotech client activity, with the company achieving a higher book-to-bill ratio for the third consecutive quarter. CFO Jill McConnell highlighted operational discipline and cost-optimisation initiatives as key drivers of margin expansion. Fortrea reaffirmed its full-year revenue guidance of $2.6 billion at the midpoint and raised EBITDA guidance to $205 million, above analyst estimates of $201.8 million. The company's market capitalisation stands at $1.42 billion.